Claim Your Author Page
On May 3, 2008, a National Cancer Institute (NCI)-sponsored open consensus conference was held in Toronto, Ontario, Canada, during the 2008 International Society for Magnetic Resonance in Medicine… (More)
To provide a comprehensive overview on vascular targeting agents and the application of radiobiological principles in pre-clinical and clinical studies, we completed a comprehensive review of… (More)
AIMS To provide a comprehensive overview of the current state of development of a novel class of anti-cancer drugs, the vascular disrupting agents (VDAs), previously known as vascular targeting… (More)
3550 Background: The vascular disruptive agent (VDA) CA4P induces significant tumor necrosis as a single agent. Vascular shut down is reversible and tumors can re-grow due to vascularisation of the...
SummaryThe intracellular localization of alkaline phosphatase was determined in human neutrophils by electron microscope cytochemistry. In normal individuals, the largest and most intense deposits of… (More)
SummaryUsing electron microscope cytochemistry and cells separated on Ficoll-Hypaque, Mg2+-dependent ATPase, ADPase and 5′-nucleotidase were predominantly localized as ectoenzymes on normal human… (More)
3551 Background: OXi4503 is the pro-drug of OXi4500 (Combretastatin A1), a tubulin binding vascular disrupting agent that also increases free radical generation. Pre-clinical studies showed that OX...
Tubulin binding vascular disrupting agents (VDAs) cause a rapid change in tumour endothelial cell shape, resulting in micro-vessel blockage, loss of blood flow, and eventually tumour cell death.… (More)